Daniel Pollyea

40PUBLICATIONS
222CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapySolid tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (40)

|Oct 08, 2026
Myeloid differentiation-associated autophagy drives venetoclax resistance in AML.

|Jul 24, 2026
A phase 1/1b study of the all-oral regimen CC-486 and venetoclax in acute myeloid leukemia.

|Jul 21, 2026
The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells.

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|May 20, 2026
RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma.

|Feb 13, 2026
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia.

Michael K Jones, Jesse Sanchez, Megan Connor

Pageof 7

Frequent Collaborators

9 joint publications

Courtney D DiNardo

8 joint publications

Craig T Jordan

7 joint publications

Maria L Amaya

6 joint publications

Angelo D'Alessandro